Abstract OT2-01-02: TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer
Year: 2020
Type: conference-abstract
Source: Cancer Research
Authors: Rashmi K Murthy, Barbara J O'Brien, Ken R Hess, Nick Navin, Jason Johnson, Maria Gule-Monroe, Jose P Leone, Jennifer Specht, Michelle Melisko, Aki Morikawa, Anna M Storniolo, Adam Brufsky, Paula R Pohlmann, Deric M Park, Ben H Park, Ian Krop, Nancy U Lin, Antonio Wolff, Andres Forerro-Torres, Erica Stringer-Reasor
Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, University of Washington, University of California, San Francisco, University of Michigan, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Pittsburgh, Georgetown Lombardi Comprehensive Cancer Center, University of Chicago, Vanderbilt University, Johns Hopkins University, Seagen (United States), University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3013830431